Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Spinal Muscular Atrophy Type 3

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Contact: Study coordinator (Kang Zhang)
Contact: Principal Investigator (Zaiqiang Zhang)
Contact: Principal Investigator (Yajie Wang)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

Spinal Muscular Atrophy · SMA · Spinal Muscular Atrophy Type 2

Abroad (travel likely)RecruitingPHASE2

Phoenix, United States · Orange, United States

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

Spinal Muscular Atrophy Type 3 · Duchenne Muscular Dystrophy (DMD)

Abroad (travel likely)Recruiting

Palo Alto, United States · Boston, United States

Gait and Bone Health in SMA

Spinal Muscular Atrophy Type 3 · Ambulatory Spinal Muscular Atrophy

Abroad (travel likely)Recruiting

New York, United States

UK SMA Patient Registry

Spinal Muscular Atrophy · SMA

Abroad (travel likely)Recruiting

Newcastle upon Tyne, United Kingdom